Esterified estrogens - GlaxoSmithKline

Drug Profile

Esterified estrogens - GlaxoSmithKline

Alternative Names: Menest

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Estradiol congeners; Hormonal replacements; Oral contraceptives
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 10 May 2004 King Pharmaceuticals has decided to market for divestiture many of its women's health products, including Menest®
  • 29 Dec 2000 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top